Phase 1 Trial of OCU500 Vaccine Shows Safety and Immunogenicity in Adults
A phase 1 trial is underway to assess the safety and immunogenicity of the OCU500 vaccine in previously vaccinated adults.
Therapeutic Area
Therapeutic area intelligence for COVID-19 Vaccine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.